Paradoxical Growth of Candida albicans in the Presence of Caspofungin Is Associated with Multiple Cell Wall Rearrangements and Decreased Virulence
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
In the last decade, echinocandins have emerged as an important family of antifungal drugs because of their fungicidal activity against Candida spp. Echinocandins inhibit the enzyme β-1,3- d -glucan synthase, encoded by the FKS genes, and resistance to echinocandins is associated with mutations in this gene. In addition, echinocandin exposure can produce paradoxical growth, defined as the ability to grow at high antifungal concentrations but not at intermediate concentrations. In this work, we have demonstrated that paradoxical growth of Candida albicans in the presence of caspofungin is not due to antifungal degradation or instability. Media with high caspofungin concentrations recovered from wells where C. albicans showed paradoxical growth inhibited the growth of a Candida krusei reference strain. Cells exhibiting paradoxical growth at high caspofungin concentrations showed morphological changes such as enlarged size, abnormal septa, and absence of filamentation. Chitin content increased from the MIC to high caspofungin concentrations. Despite the high chitin levels, around 23% of cells died after treatment with caspofungin, indicating that chitin is required but not sufficient to protect the cells from the fungicidal effect of caspofungin. Moreover, we found that after paradoxical growth, β-1,3-glucan was exposed at the cell wall surface. Cells grown at high caspofungin concentrations had decreased virulence in the invertebrate host Galleria mellonella . Cells grown at high caspofungin concentrations also induced a proinflammatory response in murine macrophages compared to control cells. Our work highlights important aspects about fungal adaptation to caspofungin, and although this adaptation is associated with reduced virulence, the clinical implications remain to be elucidated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“These antifungals are fungicidal against most Candida species and are effective against Candida isolates that are resistant to other antifungals (3).”
BackgroundResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451
Self-citationStimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins
Walker, L. A., Munro, C. A., de Bruijn, I., Lenardon, M. D., McKinnon, A., & Gow, N. A. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000040 · Cited by 445 · cited 2×
“Chitin upregulation has been described as the main adaptation mechanism involved in the paradoxical effect (15, 17, 19, 21, 23).”
BackgroundKlepser, M. E., Ernst, E. J., Lewis, R. E., Ernst, M. E., & Pfaller, M. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1207 · Cited by 338
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Dynamic, Morphotype-Specific Candida albicans β-Glucan Exposure during Infection and Drug Treatment
Wheeler, R. T., Kombe, D., Agarwala, S. D., & Fink, G. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000227 · Cited by 309 · cited 2×
“In addition, cells grown at high CAS concentrations could have different immunomodulatory properties, since caspofungin could unmask the remaining -1,3-glucan and influence its recognition by the host (42, 43, 45).”
BackgroundMunro, C. A., Selvaggini, S., De Bruijn, I., Walker, L., Lenardon, M. D., Gerssen, B., Milne, S., Brown, A. J. P., & Gow, N. A. R. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05588.x · Cited by 309
Fungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Morphogenesis and cell cycle progression in Candida albicans
Berman, J. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.10.007 · Cited by 237 · cited 1×
“First, these cells are unable to form hyphae, which are involved in adhesion, evasion, and escape from phagocytic cells (44).”
Background
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Larkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02396-16 · Cited by 395
“Other investigators showed that increasing concentrations of caspofungin treatment altered the morphology of various Candida species (30, 31).”
BackgroundFungal Cell Wall: Emerging Antifungals and Drug Resistance.
Lima, S. L., Colombo, A. L., & de Almeida Junior, J. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02573 · Cited by 223
Muszkieta, L., Aimanianda, V., Mellado, E., Gribaldo, S., Alcàzar-Fuoli, L., Szewczyk, E., Prevost, M.-C., & Latgé, J.-P. (2014) · Cellular Microbiology · doi:10.1111/cmi.12326 · Cited by 110
The eagle effect and antibiotic-induced persistence: two sides of the same coin?
Prasetyoputri, A., Jarrad, A. M., Cooper, M. A., & Blaskovich, M. A. T. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.10.007 · Cited by 101
Mesa-Arango, A. C., Rueda, C., Román, E., Quintin, J., Terrón, M. C., Luque, D., Netea, M. G., Pla, J., & Zaragoza, O. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02681-15 · Cited by 86
Self-citationRecent Insights into the Paradoxical Effect of Echinocandins
Wagener, J., & Loiko, V. (2017) · Journal of Fungi · doi:10.3390/jof4010005 · Cited by 73
“Many initial hypotheses to explain the paradoxical effect could be excluded: It has been demonstrated that paradoxical growth is not a result of resistance-associated mutations in the β-GS, upregulation of β-GS activity, inactivation, precipitation or degradation of the drug, or selection of a resistant subpopulation…”
BackgroundRueda, C., Puig-Asensio, M., Guinea, J., Almirante, B., Cuenca-Estrella, M., Zaragoza, O., Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J. R., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.016 · Cited by 58
Self-citationMoreno-Velásquez, S. D., Seidel, C., Juvvadi, P. R., Steinbach, W. J., & Read, N. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00710-17 · Cited by 57
“However, while caspofungin-mediated growth inhibition affects cell wall integrity by the reduction of -1,3-glucan, the paradoxical reversal of the growth defect observed at high concentrations of caspofungin is puzzling (19, 40).”
BackgroundLoiko, V., & Wagener, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01690-16 · Cited by 51
da Silva Dantas, A., Nogueira, F., Lee, K. K., Walker, L. A., Edmondson, M., Brand, A. C., Lenardon, M. D., & Gow, N. A. R. (2021) · Journal of Cell Science · doi:10.1242/jcs.258889 · Cited by 31
β-1,6-Glucan plays a central role in the structure and remodeling of the bilaminate fungal cell wall
Bekirian, C., Valsecchi, I., Bachellier-Bassi, S., Scandola, C., Guijarro, J. I., Chauvel, M., Mourer, T., Gow, N. A., Aimanianda, V. K., d'Enfert, C., et al. (2024) · eLife · doi:10.7554/elife.100569.3 · Cited by 28
Metadata
- Authors
- Rueda, C., Cuenca-Estrella, M., & Zaragoza, O.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-02
- Volume
- 58
- Issue
- 2
- Pages
- 1071-1083
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2124890448
- Cited by
- 98
- References
- 23
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.